Glenview Trust Co Acquires New Position in Boston Scientific Corporation $BSX

Glenview Trust Co bought a new position in shares of Boston Scientific Corporation (NYSE:BSX) during the second quarter, HoldingsChannel.com reports. The firm bought 254,089 shares of the medical equipment provider’s stock, valued at approximately $10,845,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of BSX. FWL Investment Management LLC purchased a new position in shares of Boston Scientific during the 2nd quarter worth $26,000. Swiss RE Ltd. acquired a new stake in shares of Boston Scientific during the fourth quarter worth $26,000. Garton & Associates Financial Advisors LLC purchased a new stake in shares of Boston Scientific in the fourth quarter valued at $26,000. Sfam LLC purchased a new stake in shares of Boston Scientific in the fourth quarter valued at $29,000. Finally, Cresta Advisors Ltd. acquired a new position in Boston Scientific in the fourth quarter valued at $33,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Director Susan E. Morano reportedly purchased additional Boston Scientific shares, signaling confidence from an insider while the stock is near its recent lows. Top Boston Scientific Insider Makes Bold New Share Grab
• Neutral Sentiment: The company’s latest quarterly results had been stronger than expected, with adjusted EPS and revenue exceeding consensus estimates and revenue rising year over year. However, that earnings momentum may provide limited near-term support while the cyber incident remains unresolved.
• Negative Sentiment: Boston Scientific said the cyberattack disrupted information systems used to process customer orders and ship products worldwide. The company is working to restore access, but the timing of a full recovery remains unclear, raising the risk of shipment delays, lost sales, remediation costs and weaker near-term results. Boston Scientific hit by cyberattack, global operations affected
• Negative Sentiment: The cybersecurity disruption comes alongside reports of a cardiac-device recall, increasing investor concerns about operational reliability, regulatory exposure and pressure on Boston Scientific’s growth outlook. The company has not yet quantified the financial impact of either issue. Boston Scientific hit with cardiac device recall

Boston Scientific Price Performance

BSX stock opened at $46.64 on Friday. The stock has a 50-day moving average price of $46.53 and a two-hundred day moving average price of $56.72. Boston Scientific Corporation has a 12-month low of $42.20 and a 12-month high of $109.50. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. The company has a market cap of $67.59 billion, a PE ratio of 18.88, a price-to-earnings-growth ratio of 1.05 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. The company had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The company’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same period last year, the business posted $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, research analysts predict that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific announced that its Board of Directors has initiated a stock repurchase plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s management believes its shares are undervalued.

Insider Buying and Selling

In other Boston Scientific news, Director David C. Habiger purchased 2,100 shares of Boston Scientific stock in a transaction on Wednesday, August 5th. The shares were purchased at an average cost of $47.59 per share, with a total value of $99,939.00. Following the completion of the transaction, the director directly owned 17,160 shares in the company, valued at approximately $816,644.40. This represents a 13.94% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Edward J. Ludwig acquired 5,000 shares of the company’s stock in a transaction dated Friday, July 31st. The stock was acquired at an average cost of $45.48 per share, with a total value of $227,400.00. Following the transaction, the director directly owned 30,359 shares of the company’s stock, valued at approximately $1,380,727.32. This represents a 19.72% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders acquired 194,522 shares of company stock valued at $9,385,210. 0.34% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. Zacks Research downgraded Boston Scientific from a “hold” rating to a “strong sell” rating in a research report on Friday, June 5th. TD Cowen restated a “buy” rating and issued a $56.00 price target on shares of Boston Scientific in a report on Tuesday. Bank of America dropped their price objective on shares of Boston Scientific from $105.00 to $68.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Needham & Company LLC decreased their target price on shares of Boston Scientific from $77.00 to $57.00 and set a “buy” rating on the stock in a research report on Wednesday, July 8th. Finally, Mizuho lowered their target price on shares of Boston Scientific from $90.00 to $70.00 and set an “outperform” rating for the company in a report on Wednesday, July 15th. Twenty-four research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $71.62.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.